Metrics Contract Services Adopts New Name and Logo - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Metrics Contract Services Adopts New Name and Logo

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 8

Metrics Contract Services, a contract pharmaceutical formulation development and manufacturing organization, has adopted a new and more descriptive name.

The company is unveiling a new brand look that more clearly identifies Metrics Contract Services as being part of the Mayne Pharma global family, according to a company press release.

“We know from market research that Metrics enjoys a great deal of positive brand equity with clients, who associate us with attributes such as quality, reliability, responsiveness and honesty,” said John S. Ross, executive vice president in the press release. “The new Metrics Contract Services brand identity conveys that we’re the same people, delivering the same quality experiences for clients -- and that now we’re backed by a global pharmaceutical organization with the added resources to deliver even more capabilities.”

With its more descriptive suffix, the name Metrics Contract Services better communicates an ability to deliver a full range of outsourced pharmaceutical formulation development and manufacturing capabilities, Ross said. The new logo--an adaptation of Mayne Pharma’s logo--reflects that Metrics Contract Services is a key component of the global pharmaceutical company, the company reports.

Source: Metrics Contract Services

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here